Endovascular Management of Lower Limb Claudication due to Infra-Inguinal Disease



  1. 1.
    Krankenberg H, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116(3):285–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Tepe G, et al. Drug-Coated Balloon versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and/or Popliteal Peripheral Artery Disease: 12-Month Results from the IN.PACT SFA Randomized Trial. Circulation. 2015;131(5):495–502.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rosenfield K, for the LEVANT 2 Investigators, et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015;373:145–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Tepe G. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1 Pt A):102–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Tepe G, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20(6):792–800.CrossRefPubMedGoogle Scholar
  6. 6.
    Coronary Artery angiographic changes after PTCA: Manual of Operations NHBLI PTCA Registry 1985-6:9.Google Scholar
  7. 7.
    Adlakha S, et al. Stent fracture in the coronary and peripheral arteries. J Interv Cardiol. 2010;23:411–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Iida O, et al. Effect of exercise on frequency of stent fracture in the superficial femoral artery. Am J Cardiol. 2006;98:272–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Scheinert D, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Laird JR, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Davaine JM, et al. One-year clinical outcome after primary stenting for trans-atlantic inter-society consensus (TASC) C and D femoropopliteal lesions (the STELLA “stenting long de l’artere femorale superficielle” cohort). Eur J Vasc Endovasc Surg. 2012;44:432–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Bosiers M, et al. Zilver PTX Single-Arm Study Investigators. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg. 2013;54(1):115–22.Google Scholar
  13. 13.
    Werner M, et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10(7):861–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Lin Y, et al. Stent fractures after superficial femoral artery stenting: risk factors and impact on patency. J Endovasc Ther. 2015;22(3):319–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Antoniou GA, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg. 2013;57(1):242–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Pereira CE, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006;44(3):510–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Section of Cardiovascular MedicineYale UniversityNew HavenUSA

Personalised recommendations